COVER STORY
Tiger in the Fiscal Room: Beware the Increasing Cost And Number of Orphan Drugs
While Congress worries about physicians’ salaries and employers bemoan the cost of imaging, it’s orphan drugs that might deserve most attention
Many who claim to be constructing such entities are really creating ‘clinically integrated organizations’
; Scott Guerin, PhD
Everything is relative, but there’s been what many experts describe as substantial growth for a lot reasons
These tools, often adopted by other industries, can help insurers improve health care delivery
A controversial study challenges backers to prove that these technologies are cost-effective
An MCO with an integrated medical and pharmacy benefit management system can overcome the challenges associated with this costly category
; Shannon A. Baumann, MS
PEER-REVIEWED
There was little difference between the options in terms of the frequency and cost of return visits. Patients receiving one-stage reconstructions returned slightly less often for breast-related services during the first 18 months after reconstruction, but the difference was not statistically significant.
; Nancy L. Reaven, MA ;
LEGISLATION & REGULATION
The SGR, ill-conceived and continually bypassed, may be nearing the end of its pathetic, useless life
THE FORMULARY FILES
PLAN WATCH
The insurer studies exactly what works and why in studying two programs that battle diabetes
TOMORROW’S MEDICINE
This population can benefit from Juxtapid and Kynamro, but the cost is not addressed by health reform
MANAGED CARE OUTLOOK
NEWS & COMMENTARY
NEWS & COMMENTARY
NEWS & COMMENTARY
NEWS & COMMENTARY
NEWS & COMMENTARY
NEWS & COMMENTARY
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.